Kineta Retained Earnings (Accumulated Deficit) 2014-2024 | KANT
Kineta retained earnings (accumulated deficit) from 2014 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Kineta Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-166 |
| 2022 |
$-152 |
| 2021 |
$-88 |
| 2020 |
$-148 |
| 2019 |
$-97 |
| 2018 |
$-278 |
| 2017 |
$-217 |
| 2016 |
$-157 |
| 2015 |
$-120 |
| 2014 |
$-95 |
| 2013 |
$-74 |
Kineta Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-179 |
| 2024-03-31 |
$-176 |
| 2023-12-31 |
$-166 |
| 2023-09-30 |
$-163 |
| 2023-06-30 |
$-158 |
| 2023-03-31 |
$-158 |
| 2022-12-31 |
$-152 |
| 2022-09-30 |
$-209 |
| 2022-06-30 |
$-206 |
| 2022-03-31 |
$-201 |
| 2021-12-31 |
$-88 |
| 2021-09-30 |
$-177 |
| 2021-06-30 |
$-167 |
| 2021-03-31 |
$-156 |
| 2020-12-31 |
$-148 |
| 2020-09-30 |
$-364 |
| 2020-06-30 |
$-355 |
| 2020-03-31 |
$-347 |
| 2019-12-31 |
$-97 |
| 2019-09-30 |
$-325 |
| 2019-06-30 |
$-312 |
| 2019-03-31 |
$-292 |
| 2018-12-31 |
$-278 |
| 2018-09-30 |
$-261 |
| 2018-06-30 |
$-242 |
| 2018-03-31 |
$-227 |
| 2017-12-31 |
$-217 |
| 2017-09-30 |
$-203 |
| 2017-06-30 |
$-190 |
| 2017-03-31 |
$-173 |
| 2016-12-31 |
$-157 |
| 2016-09-30 |
$-148 |
| 2016-06-30 |
$-137 |
| 2016-03-31 |
$-128 |
| 2015-12-31 |
$-120 |
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
$-95 |
| 2013-12-31 |
$-74 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.005B |
|
Kineta, Inc. is a clinical-stage biotechnology company. It develops next-generation immunotherapies that address the major challenges with current cancer therapy. The company's lead asset is KVA12123, a novel VISTA blocking immunotherapy. Kineta merged with Yumanity Therapeutics, Inc., and is based in Seattle.
|
